
Fahrettin Covut

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3887612/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival. Gastroenterology Research, 2022, 15, 56-66.	1.3	2
2	Clinical Success and Correlation of Eckardt Scores with Barium Esophagram After Peroral Endoscopic Myotomy in Achalasia. Journal of Gastrointestinal Surgery, 2021, 25, 278-281.	1.7	5
3	Direct Oral Anticoagulants Versus Warfarin and Enoxaparin in Ovarian Vein Thrombosis. American Journal of Therapeutics, 2021, 28, e260-e263.	0.9	7
4	Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria. Bone Marrow Transplantation, 2021, 56, 1458-1461.	2.4	1
5	Peroral endoscopic myotomy is equally safe and highly effective treatment option in achalasia patients with both lower and higher ASA classification status. Esophagus, 2021, 18, 932-940.	1.9	0
6	Retrospective study of clinical outcomes in patients with Stage IV HER2+ breast cancer undergoing primary breast surgery. Breast Journal, 2021, 27, 618-620.	1.0	1
7	Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. British Journal of Haematology, 2021, 193, 1213-1219.	2.5	25
8	Racial and age-related disparities in early mortality affect the outcomes of multiple myeloma patients. Leukemia, 2021, 35, 250-254.	7.2	8
9	Obesity Is Associated with Decreased Risk of Clostridium difficile Infection in Hospitalized Patients with Pouchitis. Digestive Diseases and Sciences, 2020, 65, 1423-1428.	2.3	8
10	Effects of Probiotics on Intestinal Failure–Associated Liver Disease in Adult Patients Receiving Prolonged Parenteral Support: A Tertiary Care Center Experience. Nutrition in Clinical Practice, 2020, 35, 454-463.	2.4	1
11	Evaluation of the United Kingdomâ€primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population. JGH Open, 2020, 4, 132-139.	1.6	3
12	Clinically significant bleeding with immune checkpoint inhibitors: A retrospective cohort study. European Journal of Cancer, 2020, 137, 285-287.	2.8	5
13	Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study. EClinicalMedicine, 2020, 24, 100418.	7.1	148
14	Etiology of and predictive factors for chronic intestinal failure requiring long term parenteral support in the last two decades: A retrospective study. Clinical Nutrition ESPEN, 2020, 37, 168-172.	1.2	0
15	Prevalence and Predictors of Gastrointestinal Dysmotility in Patients with Hypermobile Ehlers-Danlos Syndrome: A Tertiary Care Center Experience. Cureus, 2020, 12, e7881.	0.5	18
16	Risk of bleeding and significant thrombocytopenia in cancer patients treated with immune checkpoint inhibitors Journal of Clinical Oncology, 2020, 38, e15000-e15000.	1.6	0
17	Clinical Characteristics and Outcomes of Primary Breast Lymphoma: The Cleveland Clinic Experience. Cureus, 2020, 12, e8611.	0.5	2
18	Simultaneous Presentation of Waldenström's Macroglobulinemia and MYD88 Gene Mutation with Multiple Myeloma. Cureus, 2019, 11, e3822.	0.5	0

FAHRETTIN COVUT

#	Article	IF	CITATIONS
19	Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected. Leukemia and Lymphoma, 2019, 60, 2199-2206.	1.3	10
20	Assessment of Bleeding Risk and Cerebrovascular Events in Bipolar Disorder Patients With Atrial Fibrillation on Warfarin Versus Rivaroxaban. American Journal of Therapeutics, 2019, 26, e641-e644.	0.9	1
21	Apixaban and rivaroxaban in patients with cerebral venous thrombosis. Thrombosis Research, 2019, 173, 77-78.	1.7	27
22	Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 73-82.	0.4	1
23	Direct oral anticoagulants (DOAC) versus warfarin and enoxaparin in ovarian vein thrombosis Journal of Clinical Oncology, 2019, 37, e14698-e14698.	1.6	2
24	Hand-foot Syndrome Secondary to Low-dose Docetaxel in a Breast Cancer Patient. Cureus, 2019, 11, e4400.	0.5	0
25	Clinical characteristics and outcome of metaplastic breast cancer: A retrospective tertiary care center experience Journal of Clinical Oncology, 2019, 37, 1095-1095.	1.6	0
26	T-cell large granular lymphocytic leukemia evolution post-transplant: The Cleveland Clinic experience Journal of Clinical Oncology, 2019, 37, e19072-e19072.	1.6	0
27	Feasibility and clinical impact of next-generation sequencing (NGS) in patients with stage IV or recurrent malignancies Journal of Clinical Oncology, 2019, 37, e14697-e14697.	1.6	2
28	Impact of next-generation sequencing (NGS) in patients with high grade glioma Journal of Clinical Oncology, 2019, 37, e13541-e13541.	1.6	0
29	Impact of mastectomy in women with stage IV HER2+ breast cancer Journal of Clinical Oncology, 2019, 37, e12515-e12515.	1.6	0
30	Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. Leukemia and Lymphoma, 2018, 59, 1905-1912.	1.3	7
31	Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation. Leukemia and Lymphoma, 2018, 59, 1644-1651.	1.3	11
32	Late Central Nervous System Relapse in a Patient with Maxillary Sinus Lymphoma. Cureus, 2018, 10, e3745.	0.5	1
33	Comparison of blast clearance in peripheral blood and day 14 bone marrow biopsy for evaluation of disease response after 7+3 induction in acute myeloid leukemia (AML) Journal of Clinical Oncology, 2018, 36, 7052-7052.	1.6	0
34	Outcomes Associated with Therapeutic Anticoagulation in Patients with Brain Metastasis. Blood, 2018, 132, 1242-1242.	1.4	0
35	Nivolumab before and after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2017, 52, 1054-1056.	2.4	15
36	Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma. Blood Cancer Journal, 2017, 7, e579-e579.	6.2	40

FAHRETTIN COVUT

#	Article	IF	CITATIONS
37	Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates. JCO Clinical Cancer Informatics, 2017, 1, 1-14.	2.1	3
38	Venous thromboembolism (VTE) in multiple myeloma (MM) patients undergoing autologous hematopoietic cell transplantation (HCT) Journal of Clinical Oncology, 2017, 35, e19503-e19503.	1.6	0
39	Reducing Gastrointestinal Toxicity Associated with Autologous Transplantation for Multiple Myeloma without Compromising Its Anti-Myeloma Effect. Blood, 2017, 130, 680-680.	1.4	3
40	Rethinking Risk-Benefit Assessment for Phase I Multiple Myeloma Trials. Blood, 2016, 128, 1146-1146.	1.4	0